代谢减重手术对糖尿病缓解者与未缓解者的糖尿病管理和血糖改善效果相似
这项前瞻性观察研究纳入67名接受标准化Roux-en-Y胃旁路术的肥胖2型糖尿病成人,发现糖尿病缓解可由糖尿病病程、治疗强度、调整后HbA1c和餐后胰岛素分泌预测;缓解者与未缓解者的调整后HbA1c改善相似(−38.2 ± 17.5 mmol/mol vs. −39.5 ± 15.5 mmol/mol,p = 0.739),并在195人的英国回顾性队列中得到验证。作者建议不应将评分系统评估的糖尿病缓解可能性作为推荐代谢减重手术的标准。
要点
- 缓解者与未缓解者调整后HbA1c改善相似(−38.2 ± 17.5 mmol/mol vs. −39.5 ± 15.5 mmol/mol,p = 0.739)。
- 糖尿病缓解由糖尿病病程、治疗强度、调整后HbA1c和餐后胰岛素分泌预测。
- 作者建议不应将评分系统评估的缓解可能性作为推荐代谢减重手术的标准。
核心结论
- 未发生术后缓解者糖尿病病程更长且基线调整后HbA1c更高,但其血糖改善和治疗降级获益与缓解者相似。
- 作者建议不应将评分系统评估的糖尿病缓解可能性作为推荐代谢减重手术的标准。
研究设计与样本
- 前瞻性观察研究,发现队列纳入67名接受标准化Roux-en-Y胃旁路术的肥胖2型糖尿病成人,在英国或新加坡进行。
- 主要结局为12–15个月时的糖尿病缓解。
- 通过使用实测HbA1c及糖尿病药物剂量和类型计算调整后HbA1c,以估算无药物时的HbA1c。
- 结果通过另一英国195人接受Roux-en-Y胃旁路术的回顾性临床审计队列进行验证。
主要发现
- 糖尿病缓解由糖尿病病程、治疗强度指标及由此产生的血糖(以调整后HbA1c表示)和餐后胰岛素分泌预测。
- 发现队列中缓解者与未缓解者调整后HbA1c改善相似(−38.2 ± 17.5 mmol/mol vs. −39.5 ± 15.5 mmol/mol,p = 0.739)。
- 该发现在验证队列中得到确认。
临床怎么用
- 作者建议不应将评分系统评估的糖尿病缓解可能性作为推荐代谢减重手术的标准。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Aims Metabolic bariatric surgery (MBS), for example, Roux-en-Y gastric bypass (RYGB) can lead to diabetes remission. However, this crude dichotomous outcome fails to fully capture post-operative improvements in glycaemia and reduced medication burden in people who do not remit. The objectives of this research were to investigate predictors of diabetes remission in a multiethnic cohort and to detail post-operative improvements in glycaemia and diabetes management. Materials and Methods Prospective observational study of a discovery cohort comprising 67 adults with obesity and Type 2 diabetes, undergoing a standardised RYGB in the United Kingdom or Singapore. Diabetes remission at 12–15 months was the primary outcome. An adjusted HbA1c was calculated using measured HbA1c and the doses/types of diabetes medications to estimate HbA1c without medication. Findings were validated by retrospective clinical audit of a separate UK cohort of 195 individuals undergoing RYGB. Results Diabetes remission was predicted by diabetes duration, measures of treatment intensity and resulting glycaemia (expressed as adjusted HbA1c) and post-prandial insulin secretion. Both remitters and non-remitters in the discovery cohort showed similar improvements in adjusted HbA1c (−38.2 ± 17.5 mmol/mol vs. −39.5 ± 15.5 mmol/mol, respectively, p = 0.739), a finding confirmed in the validation cohort. Conclusions While those who do not experience post-MBS remission have a longer diabetes duration and higher baseline adjusted HbA1c, they benefit similarly from improvements in glycaemia and de-escalation of treatment as those who remit. We suggest that the likelihood of diabetes remission, as assessed by scoring systems, should not be used as a criterion to recommend MBS to patients.
引用
- Diabetes, Obesity and Metabolism:Metabolic Bariatric Surgery Leads to Similar Benefits for Diabetes Management and Glycaemia in Remitters and Non‐Remitters
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。